Search Results
Your search for ,foR matches 32731 pages
Showing 31851 - 31900Immunotherapy Strategy Boosts Survival in Metastatic Pancreatic Cancer
Overall survival was improved in patients with metastatic pancreatic cancer through an innovative immunotherapy strategy in a multicenter study to be reported at the 2014 Gastrointestinal Cancers Symposium (Abstract 177). The results were announced at a press briefing prior to the meeting....
Ramucirumab Combination Improves Overall Survival After First Progression in Patients With Metastatic Gastric Cancer
In the global phase III RAINBOW trial of patients with metastatic gastric cancer, the investigational monoclonal antibody ramucirumab significantly improved both progression-free and overall survival when given as second-line therapy, investigators reported at a press briefing in advance of the...
High Presurgical Levels of Angiogenic and Growth Factors Are Associated With Poorer Survival After Gastric Resection
In patients undergoing gastric resection for gastric/gastroesophageal junction cancers, high levels of angiogenic and growth factors are associated with poorer overall survival, according to the results of a retrospective study presented by Park et al in the Annals of Surgical Oncology. Thus, these ...
Multiple Myeloma Study Shows Widespread Genetic Heterogeneity
A detailed study of tissue samples from more than 200 patients with multiple myeloma has found that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. The result could have therapeutic ramifications for future patients, according to study...
RAS Status Predicts Response to Second-Line Treatment With Panitumumab for Metastatic Colorectal Cancer
New data from a phase III clinical trial shows that patients with metastatic colorectal cancer tumors that contain RAS mutations beyond KRAS exon 2 are unlikely to benefit from the addition of panitumumab (Vectibix) to second-line FOLFIRI (leucovorin, fluorouracil, irinotecan) chemotherapy....
Preoperative Oral Capecitabine Chemotherapy Is Equivalent to Infusional 5-FU for Rectal Cancer
New findings from a four-arm phase III clinical trial in patients with stage II or stage III rectal cancer indicate that combining preoperative radiation with either capecitabine or fluorouracil (5-FU) results in equivalent outcomes. This study provides strong clinical evidence that using either...
Combination Capecitabine/Temozolomide Appears Highly Effective in Patients With Treatment-Resistant Neuroendocrine Tumors
Interim results from an ongoing phase II clinical trial in patients with various types of advanced neuroendocrine tumors show that a new chemotherapy combination of capecitabine and temozolomide either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after...
No Increased Risk of Local Recurrence After Breast-Conserving Surgery in Triple-Negative Breast Cancer in Single-Center Study
Triple-negative breast cancer may be considered a relative contraindication to breast-conserving surgery. In a study reported in JAMA Surgery, Gangi et al from Cedars-Sinai Medical Center in Los Angeles assessed outcomes in a large cohort of women undergoing breast-conserving surgery at their...
Superior Progression-Free Survival With Obinutuzumab/Chlorambucil vs Rituximab/Chlorambucil in Previously Untreated CLL With Coexisting Conditions
Obinutuzumab (Gazyva) is a glycoengineered type 2 anti-CD20 antibody that appears to exhibit increased activity against chronic lymphocytic leukemia cells (CLL), with increased antibody-dependent cellular cytotoxicity and reduced complement-dependent cytotoxicity, compared with rituximab (Rituxan). ...
Smoking Prevalence Declines Among Health-Care Professionals
In a study reported as a research letter in JAMA, Sarna et al found that the prevalence of smoking among U.S. health-care professionals was 8.3% in 2010/2011, representing decreases of 23.4% since 2003 and 19.3% since 2006/2007. A previous study had shown no marked reduction in smoking rates among...
Dabrafenib Receives FDA Breakthrough Therapy Designation for BRAF-Mutated NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for dabrafenib (Tafinlar) for the treatment of patients with metastatic BRAF V600E mutation–positive non–small cell lung cancer (NSCLC) who have received at least one prior line of...
FDA Accepts New Drug Application for Idelalisib in Refractory Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for idelalisib, a targeted, oral inhibitor of PI3K-delta, for the treatment of refractory indolent non-Hodgkin lymphoma (NHL). The FDA has granted a standard review for the NDA, with a target review date of...
Known Lung Cancer Oncogenes ALK and ROS1 May Also Drive Certain Colorectal Tumors
ALK and ROS1 gene rearrangements, which are known to drive subsets of lung cancer, appear to be present in some colorectal cancers as well, according to the results of a study published in Molecular Cancer Research. The findings by Aisner et al suggest that therapies used to target these two...
Quadrivalent HPV Vaccine Provides Poorer Protection in Women 18 and Older or With Abnormal Cytology
In a study reported in the Journal of Clinical Oncology, Mahmud et al evaluated the effectiveness of the quadrivalent human papillomavirus (HPV) vaccine against cervical dysplasia using population-based individual level data routinely collected in Manitoba. They found that a high proportion of...
Ibrutinib Promising as Initial Therapy for Elderly Patients With CLL in Phase IB/II Trial
Chemoimmunotherapy has produced improved response and survival in young patients with chronic lymphocytic leukemia (CLL), but its use in elderly patients has been limited by myelosuppression and infection. In a phase IB/II study reported in The Lancet Oncology, O’Brien et al assessed the use...
Short-Term Follow-up Reveals Suboptimal Pain Relief and Marked Pain Worsening in Ambulatory Cancer Patients
In an analysis reported in the Journal of Clinical Oncology, Zhao et al assessed factors associated with pain severity changes in ambulatory patients with solid tumors in the Eastern Cooperative Oncology Group E2Z02 (Symptom Outcomes and Practice Patterns) trial. They found that approximately...
Nurse- and Gastroenterologist-Led Algorithm-Based Management Improve GI Symptoms After Pelvic Radiotherapy
In the ORBIT trial, reported in The Lancet, Andreyev et al compared outcomes with usual care, gastroenterologist-led algorithm-based management, and nurse-led algorithm-based management for patients with chronic gastrointestinal symptoms following pelvic radiotherapy for cancer. The findings...
Meta-Analysis Indicates No Reduction in Risk of Local or Distant Breast Cancer Recurrence With Preoperative Staging MRI
In an individual patient data meta-analysis reported in the Journal of Clinical Oncology, Houssami et al found that preoperative magnetic resonance imaging (MRI) was not associated with differences in local recurrence or distant recurrence compared with conventional imaging in women with breast...
Chemotherapy Drug Shortages Threaten Quality of Treatment
Over the past several years, there have been recurring shortages of widely used generic chemotherapy agents in the United States. In a letter to The New England Journal of Medicine, Gogineni et al described a survey of U.S. oncologists regarding types and frequency of chemotherapy shortages and...
Web-Based Self-Care Support and Communication Coaching Program Reduces Symptom Distress in Cancer Patients
In the ESRA-CII trial reported in the Journal of Clinical Oncology by Berry et al, patient use of a Web-based self-care program featuring tailored education and communication coaching resulted in significantly reduced symptom distress compared with symptom/quality-of-life tracking alone in patients ...
Half of Patients With Stage I Pediatric Malignant Ovarian Germ Cell Tumors Can Be Spared Chemotherapy After Initial Surgery With Surveillance Strategy
In a Children’s Oncology Group study (AGCT0132) reported in the Journal of Clinical Oncology, Billmire et al found that overall survival can be preserved in patients with stage I pediatric malignant ovarian germ cell tumor with a strategy of initial surveillance after surgical resection....
FDA Approves Combination Therapy for Unresectable or Metastatic Melanoma With BRAF V600E/K Mutations
The U.S. Food and Drug Administration (FDA) has approved trametinib (Mekinist) for use in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved...
Major Decline in Lung Cancer Reported
“Eliminating tobacco use is the most important thing we can do to prevent lung and other cancers, as well as the many other diseases its use causes. Today’s news confirms that we are making progress. However, the global health challenges from tobacco are still growing. “This new...
Rates of New Lung Cancer Cases Drop in U.S. Men and Women
Tobacco control efforts are having a major impact on Americans’ health, a new analysis of lung cancer data suggests. The rate of new lung cancer cases decreased among men and women in the United States from 2005 to 2009, according to a report in this week’s Morbidity and Mortality...
Sentinel Lymph Node Biopsy Associated With Survival Advantage in Merkel Cell Carcinoma
In patients with Merkel cell carcinoma, sentinel lymph node biopsy was shown to be associated with improved survival, according to the results of a retrospective study reported by Kachare et al in the Annals of Surgical Oncology. Thus, sentinel lymph node biopsy offers prognostic information that...
Good Results Using Loss of Major Molecular Response as Criterion for Restarting Tyrosine Kinase Inhibitor Therapy in CML
Many patients with chronic-phase chronic myelogenous leukemia (CML) in complete molecular response have molecular relapse after discontinuation of imatinib (Gleevec) treatment. In a French multicenter observational study reported in the Journal of Clinical Oncology, Rousselot et al assessed the...
No Benefit of Adding Tirapazamine to Cisplatin Chemoradiation in Locally Advanced Cervical Cancer
In a phase III intergroup trial (Gynecologic Oncology Group Protocol 219) reported in the Journal of Clinical Oncology, DiSilvestro et al in the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group evaluated the addition of the hypoxic cell sensitizer...
Higher Copayment Associated With Greater Discontinuation of and Nonadherence to Tyrosine Kinase Inhibitor Treatment in CML
The availability of the tyrosine kinase inhibitor imatinib (Gleevec) has dramatically increased survival in chronic myeloid leukemia (CML). Nonadherence to therapy with imatinib and other tyrosine kinase inhibitors is associated with disease progression and treatment resistance. In a study reported ...
No Survival Benefit of Erlotinib in EGFR-Unselected Patients With Nonprogressing Ovarian Cancer After Platinum Therapy
EGFR is overexpressed in the majority of advanced epithelial ovarian carcinomas, and there is evidence indicating that overexpression is associated with poorer prognosis. In a phase III European Organisation for Research and Treatment of Cancer (EORTC)-Gynaecological Cancer Group and Gynecologic...
Survey Finds Many General Internists Are Uncomfortable Caring for Adult Survivors of Childhood Cancer
A National Cancer Institute–funded survey of general internists asking about their attitudes and knowledge about the care of adult childhood cancer survivors has found that few internists are comfortable caring for these patients. Moreover, many are unfamiliar with the Children’s...
Renal Cell Carcinoma Onset at ≤ 46 Years Could Serve as Marker for Genetic Testing
Approximately 5% to 8% of renal cell carcinoma cases are hereditary, and there are no guidelines for patient selection for germline mutation testing in this disease. In a study reported in the Journal of Clinical Oncology, Shuch et al from the National Cancer Institute assessed whether age at onset ...
ASCO Issues Statement in Response to American Cancer Society Report
Today the American Cancer Society issued a report showing a 20% decline in cancer death rates between 1991 and 2010, and estimating that 1.3 million deaths have been averted as a result of the decline. ASCO issued the following statement: “This is tremendous progress and a direct result ...
Most Physicians Would Enroll in Hospice If They Were Terminally Ill With Cancer, Study Finds
In a research letter published in JAMA Internal Medicine, Chinn et al surveyed physicians’ attitudes towards hospice treatment if they were terminally ill with cancer and assessed how physician preferences might affect timing of hospice discussions with their terminally ill patients. They...
Preclinical Study Suggests E-Cigarettes May Contribute to Lung Cancer in High-Risk Individuals
A study of human bronchial epithelial cells carrying mutations in the TP53 and KRAS genes has found that e-cigarette vapors enhanced the cells’ cancerous behaviors. The study suggests that e-cigarette exposure may contribute to lung cancer in individuals at high risk for the disease. The...
Matched-Pairs Analysis Shows Better Survival With Allogeneic Transplantation vs Conventional Chemotherapy in Postremission Therapy for AML
In a prospective matched-pairs analysis reported in the Journal of Clinical Oncology, Stelljes et al in the German AML Cooperative Group compared outcomes with allogeneic stem cell transplantation vs conventional postremission chemotherapy in patients aged < 60 years with acute myeloid leukemia...
Single Fractions of Radiation for Painful Bone Metastases May Be Noninferior to Multiple Fractions
Optimal dose fractionation for radiation therapy of painful bone metastases from multiple primary sites remains undefined. In a phase III noninferiority trial reported in The Lancet Oncology, Chow et al compared 8 Gy in a single fraction vs 20 Gy in multiple fractions in patients with painful bone...
Imprime PGG Added to Chemoimmunotherapy Shows Improved Outcomes in Advanced Lung Cancer Patients
The addition of Imprime PGG, a type of immunotherapy, to chemoimmunotherapy with carboplatin, paclitaxel, and cetuximab (Erbitux) resulted in improved response rates and overall survival rates in patients with late-stage, non–small cell lung cancer (NSCLC), according to the results of a phase ...
No Survival Difference for Autologous vs Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Chemotherapy-Sensitive Mantle Cell Lymphoma
In an analysis reported in the Journal of Clinical Oncology, Fenske et al compared outcomes with early or late autologous vs reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in a population of patients with chemotherapy-sensitive mantle cell lymphoma. They found no...
Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
Phase II Pilot Study Does Not Support Phase III Investigation of IV High-Dose Interferon Without Maintenance in Resected Melanoma
There is evidence that high-dose interferon alfa-2b consisting of 4 weeks of daily intravenous interferon alfa-2b followed by 48 weeks of subcutaneous maintenance interferon alfa-2b three times per week reduces risk of recurrence of resected melanoma and that response may depend on the early...
Study Evaluates Risk of Depression by Race and Sex Among Patients With Newly Diagnosed Lung Cancer
In a study reported in the Journal of Clinical Oncology, Traeger et al evaluated risk of depression symptoms and psychosocial service use by race and sex among patients with newly diagnosed lung cancer. The investigators found that black men have the highest prevalence of depressive symptoms, white ...
No Difference for Aprepitant vs Dexamethasone for Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer
In a phase III study reported in the Journal of Clinical Oncology, Roila et al compared aprepitant vs dexamethasone in prevention of delayed emesis in breast cancer patients treated with anthracycline/cyclophosphamide who had received palonosetron/aprepitant/dexamethasone prophylaxis for acute...
Oral Insulin Sensitizers Associated With Decreased Cancer Risk in Women With Type 2 Diabetes
According to the findings of a meta-analysis by Sun et al published in Diabetes, Obesity, and Metabolism, patients with type 2 diabetes mellitus who are on certain therapies, such as insulin secretagogues, may be at higher risk for cancer. This increased risk was seen more frequently in women, and...
‘Faster and Deeper Responses’ With Dasatinib vs Imatinib in Chronic-Phase CML Patients
Dasatinib (Sprycel) resulted in “faster and deeper responses” compared to imatinib (Gleevec) among patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML), according to a 3-year follow-up of the randomized phase III DASISION (Dasatinib vs Imatinib Safety In...
Imiquimod 5% Cream Inferior to Surgical Excision in Nodular and Superficial Basal Cell Carcinoma
In a noninferiority trial (SINS) reported in The Lancet Oncology, Bath-Hextall et al compared imiquimod 5% cream vs surgical excision for nodular and superficial basal cell carcinomas. Imiquimod cream was found to be inferior to surgical excision, but it may have a role in treatment of low-risk...
Neoadjuvant Paclitaxel Before Anthracycline Improves Response in High-Risk Early Breast Cancer
In a phase III 2×2 factorial trial (Neo-tAnGo) reported in The Lancet Oncology, Earl et al compared neoadjuvant therapy with epirubicin/cyclophosphamide followed by paclitaxel with or without gemcitabine vs paclitaxel with or without gemcitabine followed by epirubicin/cyclophosphamide in ...
Wider Surgical Margins Do Not Appear To Reduce Local Recurrence Rates in Triple-Negative Breast Cancer
Wider surgical margins did not reduce the rate of local recurrence in women with triple-negative breast cancer treated with breast-conserving therapy, according to the results of a study published in the Annals of Surgical Oncology. Pilewskie et al reported that their data support the definition of ...
FDA Approves Revised Prescribing Information for Ponatinib, Authorizes Resumption of Drug Sales and Distribution
The U.S. Food and Drug Administration (FDA) has approved revised prescribing information and a Risk Evaluation and Mitigation Strategy (REMS) for ponatinib (Iclusig) that allows immediate resumption of its marketing and commercial distribution. The prescribing information includes a revised...
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year
While acknowledging that the full potential of cancer immunotherapy remains unclear, the editors of the journal Science said that the approach of using the immune system to attack tumors marks a turning point in the treatment of cancer. The successes of cancer immunotherapy in clinical trials in...
Oral Ibandronic Acid Is Not Noninferior to IV Zoledronic Acid in Preventing Skeletal-Related Events in Patients With Breast Cancer
In a phase III noninferiority trial (ZICE) reported in The Lancet Oncology, Barrett-Lee et al compared oral ibandronic acid vs intravenous zoledronic acid in treatment of bone metastases from breast cancer. The study showed that ibandronic acid was not noninferior to zoledronic acid in preventing...
